Everything below concerns freeze-thaw. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analog of the tetrapeptide tuftsin |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Reported consistently across pharmacopoeial descriptions |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| Solubility | Freely soluble in water | Aqueous buffers; poor in nonpolar solvents |
| Typical storage temperature | -20 degrees Celsius | Lyophilized powder; protect from moisture |
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.
Solubility behavior is a practical concern for handling. Selank dissolves readily in water and in common aqueous buffers, which simplifies preparation of working solutions. The choice of solvent, ionic strength, and pH can influence aggregation over time, particularly at higher concentrations. Aqueous solutions are typically sterile-filtered before use. Because stability depends on several variables, storage and handling notes should be treated as general guidance rather than fixed rules, and specific values are best confirmed against a certificate of analysis for each batch.
Characterization of Selank in a laboratory setting relies on standard peptide methods. Reverse-phase high-performance liquid chromatography separates the target from related impurities and provides a purity figure, commonly reported as 95 percent or higher. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, confirms the molecular mass and helps detect truncation or modification. Amino acid analysis can verify composition when a sequence-level check is needed. These techniques together establish identity and purity for a given lot.
==== Added sugars ==== While it is not necessary to limit the sugars found naturally in whole, unprocessed foods like fresh fruit, eating too much added sugar found in many processed foods increases the risk of heart disease, obesity, cavities and Type 2 diabetes. The American Heart Association recommends women limit added sugars to no more than 420 kilojoules (100 kilocalories), or 25 grams, and men limit added sugars to no more than 650 kJ (155 kcal), or about 38.75 grams, per day. Currently, Americans consume an average of 1,490 kJ (355 kcal) from added sugars each day.
=== Regulation of gene expression === The activated IRS-1 acts as a secondary messenger within the cell to stimulate the transcription of insulin-regulated genes. First, the protein Grb2 binds the P-Tyr residue of IRS-1 in its SH2 domain. Grb2 is then able to bind SOS, which in turn catalyzes the replacement of bound GDP with GTP on Ras, a G protein. This protein then begins a phosphorylation cascade, culminating in the activation of mitogen-activated protein kinase (MAPK), which enters the nucleus and phosphorylates various nuclear transcription factors (such as Elk1).
=== Cosmetics === Some hair shampoos on the market include estrogens and placental extracts; others contain phytoestrogens. In 1998, there were case reports of four prepubescent African-American girls developing breasts after exposure to these shampoos. In 1993, the FDA determined that not all over-the-counter topically applied hormone-containing drug products for human use are generally recognized as safe and effective and are misbranded. An accompanying proposed rule deals with cosmetics, concluding that any use of natural estrogens in a cosmetic product makes the product an unapproved new drug and that any cosmetic using the term "hormone" in the text of its labeling or in its ingredient statement makes an implied drug claim, subjecting such a product to regulatory action. In addition to being considered misbranded drugs, products claiming to contain placental extract may also be deemed to be misbranded cosmetics if the extract has been prepared from placentas from which the hormones and other biologically active substances have been removed and the extracted substance consists principally of protein. The FDA recommends that this substance be identified by a name other than "placental extract" and describing its composition more accurately because consumers associate the name "placental extract" with a therapeutic use of some biological activity.
== Advantages == The bio/pharma companies used to build and staff dedicated manufacturing capacities for drugs in development only to see them canceled if the product failed in Phase III of clinical research; working with a CDMO limits that financial risk. Using a CDMO also allows drug and biologic manufacturers to get advantage of specific expertise and capability. Some CDMOs are specialized in manufacturing of specialty products or formulations which some pharmaceutical companies may not have the capability to produce in-house. In these situations, contracting with a CDMO may be a faster and less costly solution than developing new manufacturing capabilities. Accelerated development timelines In addition to reducing cost and providing specialized expertise, CDMOs can also shorten the time needed to bring drug candidates to regulatory submission. A 2025 report by PharmaSource described a small-molecule program managed by the CDMO BioDuro that advanced to Investigational New Drug (IND) submission in approximately 11 months, compared to the multi-year timelines often seen in traditional development. The acceleration was attributed to parallel workstreams in active pharmaceutical ingredient (API) synthesis and drug-product formulation, a unified quality system, and dedicated project management support that streamlined communication between teams.
Sources: en.wikipedia.org
== External links == Nutmeg - Erowid Nutmeg Reports - Erowid Experience Vaults - Erowid Nutmeg - PsychonautWiki The Big & Dandy Nutmeg Thread - Bluelight Myristicin - Isomer Design Myristica fragrans: An Exploration of the Narcotic Spice (2008) - Ibo Nagano - The Entheogen Review - Erowid
Action – Batman: Arkham City Artistic Achievement – Rayman Origins Audio Achievement – Battlefield 3 Best Game – Portal 2 Debut Game – Insanely Twisted Shadow Planet Family – LittleBigPlanet 2 Game Design – Portal 2 Game Innovation – LittleBigPlanet 2 Mobile & Handheld – Peggle HD Online – Browser – Monstermind Online Multiplayer – Battlefield 3 Original Music – L.A. Noire Performer – Mark Hamill (as The Joker, Batman: Arkham City) Sports/Fitness – Kinect Sports: Season Two Story – Portal 2 Strategy – Total War: Shogun 2 BAFTA Ones To Watch Award (in association with Dare to Be Digital) – Tick Tock Toys GAME Award of 2011 – Battlefield 3 Special – Markus Persson
An adnexal mass is a lump in the tissue of the adnexa of the uterus (structures which are closely related structurally and functionally to the uterus, such as the ovaries, fallopian tubes, or any of the surrounding connective tissue). Adnexal masses can be benign (noncancerous) or malignant (cancerous), and they can be categorized as simple or complex.
Sources: en.wikipedia.org
=== Wound healing === Vascularization is crucial for wound healing, as it provides oxygen and nutrients necessary for tissue repair. Angiogenesis temporarily increases vascular density around the wound, aiding the healing process. Vascular endothelial growth factor (VEGF) is a key pro-angiogenic factor in this process, stimulating both vasculogenesis and angiogenesis in the skin. Impaired angiogenesis can result in delayed wound healing, as seen in conditions such as diabetes, where chronic wounds often exhibit reduced levels of active VEGF. Therapeutic stimulation of angiogenesis is being explored to speed up healing, especially in persistent wounds.
The decrease in BMD during elagolix therapy may not be fully reversible with discontinuation, as only partial recovery was observed 12 months after discontinuation of therapy. The cause of the decrease in BMD with elagolix is estrogen deficiency, and is analogous to that associated with postmenopause. The consequences of the effects of elagolix on BMD are unknown, but may be an increase in the risk of bone loss and fractures. This is why the duration of use of elagolix should be limited. In women with risk factors for bone loss and osteoporosis, such as a history of low-trauma fracture, assessment of BMD may be considered. Elagolix should not be used in premenopausal women with known osteoporosis. Supplementation with calcium and/or vitamin D during treatment with elagolix has not been studied, but may be beneficial for helping to maintain bone health. Elagolix decreases the amount, intensity, and duration of menstrual bleeding. Amenorrhea, the cessation of menstruation, was observed in 4 to 17% of women with 150 mg once per day and in 7 to 57% of women with 200 mg twice per day, compared to less than 1% of women given placebo. The decreased menstrual bleeding caused by elagolix may impede the ability to recognize pregnancy in a timely manner. Based on its mechanism of action, elagolix may increase the risk of miscarriage in early pregnancy, and so should be discontinued if pregnancy occurs. If pregnancy is suspected, pregnancy testing can be performed.
24 June – David Hinton, the chief executive of South East Water, has blamed the increase in people working from home as a result of the COVID-19 pandemic for the implementation of a planned hosepipe ban on 26 June, with an estimated 20% increase in the use of drinking water in commuter towns. 25 June – Avon and Somerset Police confirm that a man in his 40s has died following a "medical incident" at the 2023 Glastonbury Festival. 26 June – An inquest opens into the death of Nicola Bulley. 27 June – The inquest into the death of Nicola Bulley returns a verdict of accidental death. Sarah Bentley resigns as chief executive of Thames Water after previously forgoing her bonus after raw sewage became a problem for the company. Nurses in England will not continue their strike action after a Royal College of Nursing ballot failed to garner enough votes to achieve a mandate. The majority of the 43% who voted favoured continued strike action, but this was below the 50% turnout required under trade union regulations. Senior consultants in England will begin strike action after 86% of those who took part in a ballot voted to take strike action; a previously announced 48-hour strike will now go ahead from 21 July. 28 June – The second Test match of the 2023 Ashes series is briefly interrupted when Just Stop Oil protestors invade the pitch at Lord's. Thames Water is reported to be in talks with the UK government to secure extra funding amid concerns the company is on the brink of collapse. 29 June – Sir John Mitting's interim report for the Undercover Policing Inquiry is published.
=== Protein sequencer === A protein sequenator is a machine that performs Edman degradation in an automated manner. A sample of the protein or peptide is immobilized in the reaction vessel of the protein sequenator and the Edman degradation is performed. Each cycle releases and derivatises one amino acid from the protein or peptide's N-terminus and the released amino-acid derivative is then identified by HPLC. The sequencing process is done repetitively for the whole polypeptide until the entire measurable sequence is established or for a pre-determined number of cycles.
Sources: en.wikipedia.org
Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.
The first four residues of Selank reproduce the tuftsin sequence Thr-Lys-Pro-Arg. A Pro-Gly-Pro extension at the C-terminus was added to slow enzymatic breakdown and extend residence time.
It holds marketing authorization in Russia, where nasal drop formulations are sold. No equivalent approval exists in the European Union, the United States, or most other countries.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.